Cambridge, United Kingdom

Christopher Worrall


Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 14(Granted Patents)


Location History:

  • Camridge, GB (2017)
  • Cambridge, GB (2019)

Company Filing History:


Years Active: 2017-2019

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Christopher Worrall

Introduction

Christopher Worrall is a prominent inventor based in Cambridge, GB. With a total of two registered patents, he has made significant contributions to the field of pharmaceuticals, particularly in the development of new compounds with potential therapeutic applications.

Latest Patents

Worrall's recent patents focus on polymorphic forms of a hydrochloride salt of a novel compound: (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. These innovations include the disclosure of various polymorphs and solvent forms of this hydrochloride salt, along with their compositions, methods for preparation, and potential uses. This work not only enhances the understanding of the compound's properties but also paves the way for more effective pharmaceutical applications.

Career Highlights

Working with Gilead Calistoga LLC, Christopher Worrall has been an integral part of the team, contributing to groundbreaking research and development efforts. His work is pivotal to advancing medical science and improving treatment strategies in the pharmaceutical industry.

Collaborations

Throughout his career, Worrall has collaborated with esteemed colleagues, including Suzanne Buttar and Ernest A. Carra. These partnerships foster a collaborative environment that encourages the exchange of ideas and enhances innovative capabilities.

Conclusion

Christopher Worrall’s contributions through his innovative patents signify important advancements in pharmaceutical research. His work serves as an inspiration for future inventors and highlights the vital role of collaboration in driving innovation. As he continues to explore new horizons in his field, the potential for further breakthroughs remains promising.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…